Search results
As the leader in RNA-targeted therapeutics for more than three decades, Ionis has focused every moment on advancing drug discovery, development, and providing hope for patients.
Ionis: A force for life. We are guided by world-class scientists and business leaders whose drive and passion to innovate is matched only by their commitment to deliver first-in-class and best-in-class medicines to the patients who need them. View 2023 Corporate Responsibility Report ».
Ionis currently has five marketed medicines and a leading pipeline in neurology, cardiology, and other areas of high patient need. As the pioneer in RNA-targeted medicines, Ionis continues to drive innovation in RNA therapies in addition to advancing new approaches in gene editing.
Ionis Pharmaceuticals, Inc. is a biotechnology company based in Carlsbad, California, that specializes in discovering and developing RNA-targeted therapeutics.
Find the latest Ionis Pharmaceuticals, Inc. (IONS) stock quote, history, news and other vital information to help you with your stock trading and investing.
Our antisense therapies are designed to interact precisely with RNA, allowing us to create treatments that disrupt the disease process and change its course. With five marketed medicines and 10+ in mid- or late-stage development, our therapeutic breakthroughs are poised to continue to transform the futures of patients for years to come.
May 16, 2024 · ION582 demonstrated consistent improvements across multiple functional domains in Angelman syndrome patients. ION582 was safe and well tolerated at all dose levels. Ionis plans to move ION582 into pivotal trial.
